Biotechnology
Price
$261.07
+3.99%Market Cap
$461.26B
Day High
$261.63
Day Low
$250.51
AbbVie delivered strong Q1 FY2026 revenue growth of 12.4% to $15.0B, but net income fell 46.0% to $695M, driven by elevated costs and below-the-line charges, even as operating cash flow surged 134.2% to $3.83B.
Key risk: Negative Stockholders' Equity and High Leverage
AbbVie's stockholders' equity deteriorated to -$6.66B in Q1 FY2026 from +$1.42B a year ago, a decline of nearly 569%. This reflects the company's heavy debt load from the Allergan acquisition combined with aggressive shareholder returns, leaving the balance sheet technically insolvent on a book-value basis and vulnerable to credit market disruptions.
Other Biotechnology companies